Literature DB >> 24398877

Upregulation of miR-194 contributes to tumor growth and progression in pancreatic ductal adenocarcinoma.

Jing Zhang1, Chen-Yan Zhao1, Shu-Hui Zhang2, Dang-Hui Yu1, Ying Chen1, Qing-Hua Liu1, Min Shi1, Can-Rong Ni1, Ming-Hua Zhu1.   

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal types of human cancer worldwide. In the present study, we investigated the diagnostic and biological significance of microRNA-194 (miR-194) in PDAC. miRNA expression profiling of human PDACs and adjacent normal pancreatic tissues identified a total of 16 genes including miR-194 with >1.15-fold expression changes (8 overexpressed and 8 underexpressed). Quantitative real-time polymerase chain reaction (PCR) revealed elevation of serum miR-194 levels were significantly greater in PDAC patients than in duodenal adenocarcinoma patients and healthy controls. Receiver operating characteristic analysis demonstrated that serum miR-194 had a sensitivity of 54.3% and a specificity of 57.5% for discriminating PDAC patients from healthy controls. Combined analysis of the 3 groups yielded a sensitivity of 84.0 and a specificity of 75.0% for the combined detection of miR-192 and miR-194 in the diagnosis of PDAC. Ectopic expression of miR-194 in PANC-1 pancreatic cancer cells enhanced cell proliferation, migration and colony formation, which was coupled with decreased expression of the tumor suppressor DACH1. miR-194 overexpression increased tumor growth and local invasion and suppressed the expression of DACH1 in an orthotopic pancreatic cancer mouse model. In conclusion, upregulation of miR-194 contributes to tumor growth and progression in PDAC, possibly through suppression of DACH1. However, serum miR-194 has a low capacity for detection of PDAC. Combined detection of serum miR-192 and miR-194 levels may serve as a sensitive diagnostic biomarker for PDAC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24398877     DOI: 10.3892/or.2013.2960

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  40 in total

1.  MicroRNAs as novel biomarkers for pancreatic cancer diagnosis: a meta-analysis based on 18 articles.

Authors:  Zhongyang Ding; Haorong Wu; Jiaming Zhang; Guorong Huang; Dongdong Ji
Journal:  Tumour Biol       Date:  2014-06-02

Review 2.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

3.  miR-128 induces pancreas cancer cell apoptosis by targeting MDM4.

Authors:  Hongchao Han; Lisheng Wang; Jie Xu; Aikun Wang
Journal:  Exp Ther Med       Date:  2018-04-10       Impact factor: 2.447

4.  MiR-194, commonly repressed in colorectal cancer, suppresses tumor growth by regulating the MAP4K4/c-Jun/MDM2 signaling pathway.

Authors:  Bo Wang; Zhan-long Shen; Zhi-dong Gao; Gang Zhao; Chun-you Wang; Yang Yang; Ji-zhun Zhang; Yi-chao Yan; Chao Shen; Ke-wei Jiang; Ying-jiang Ye; Shan Wang
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

5.  Diagnosis of Pancreatic Cancer Using miRNA30e Biosensor.

Authors:  Namita Sharma; Sudha Srivastava
Journal:  Interdiscip Sci       Date:  2022-07-03       Impact factor: 3.492

6.  Promotional effect of microRNA-194 on breast cancer cells via targeting F-box/WD repeat-containing protein 7.

Authors:  Yaomin Chen; Haiyan Wei; Yu Liu; Shusen Zheng
Journal:  Oncol Lett       Date:  2018-01-23       Impact factor: 2.967

Review 7.  MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions.

Authors:  Yasmin G Hernandez; Aimee L Lucas
Journal:  World J Gastrointest Oncol       Date:  2016-01-15

Review 8.  Pancreatic Ductal Adenocarcinoma: MicroRNAs Affecting Tumor Growth and Metastasis in Preclinical In Vivo Models.

Authors:  Ulrich H Weidle; Fabian Birzele; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2019 Nov-Dec       Impact factor: 4.069

9.  N6-methyladenosine demethylase ALKBH5 suppresses malignancy of esophageal cancer by regulating microRNA biogenesis and RAI1 expression.

Authors:  Pengxiang Chen; Song Li; Ke Zhang; Renchang Zhao; Jianfeng Cui; Wei Zhou; Yuchen Liu; Lin Zhang; Yufeng Cheng
Journal:  Oncogene       Date:  2021-07-26       Impact factor: 9.867

Review 10.  Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Geeta G Sharma; Yasuyuki Okada; Daniel Von Hoff; Ajay Goel
Journal:  Semin Cancer Biol       Date:  2020-10-10       Impact factor: 17.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.